Metformin and exercise in cancer: Better together
Mené sur 139 patients ayant survécu à un cancer colorectal ou à un cancer du sein, cet essai de phase II évalue l'effet de la metformine et d'exercices physiques, seuls ou en combinaison, sur les niveaux sériques à jeun d'insuline et d'autres biomarqueurs métaboliques
The levels of obesity in the general population are reaching epidemic proportions. Over the last 40 years, the prevalenceof obesity in the United States has tripled and the World Health Organization estimates that worldwide, 650 million individuals over the age of 18are obese. While it has long been recognized that obesity is a key risk factor in the etiology of type 2 diabetes and cardiovascular disease, emerging evidence indicates that obesity is an adverse factor in the development and severity of many human cancersincluding those of the breast and colon (1,2). Obesity is associated with changes in the levels of a varietyof systemic physiological factors that may contribute to tumorigenesis and reduced patient outcomes,including adipokines, sex hormones, inflammatory cytokines, glucose and insulin. There is great interest in modulating these factors through medications or lifestyle interventions for the prevention and/ortreatment of cancer.
JNCI Cancer Spectrum , commentaire, 2018